Sanofi (SASY.PA) is considering a bid for Swiss biotech company Actelion (ATLN.S), rivaling an offer made by U.S. healthcare company Johnson & Johnson (JNJ.N), Bloomberg reported.
French drugmaker Sanofi is working with advisers to assess its options, people familiar with the matter told Bloomberg. (bloom.bg/2h8qooh)
Sanofi has made its interest known to Actelion but has not decided if it will proceed with a bid, Bloomberg said, citing the sources.
J&J said last month it was in preliminary talks with Actelion about a takeover of Europe’s largest biotech firm, which was then valued at about $20 billion.
Lung disease specialist Actelion, which confirmed the J&J move then, had warned that there was no certainty of a deal.
Sanofi, J&J, Actelion, Roche, and Pfizer were not immediately available for comments.
Recent Articles on M&A
Source: Reuters.com
